|
|
||||||||
J Thorac Cardiovasc Surg 1998;116:617-623
© 1998 Mosby, Inc.
CARDIOTHORACIC TRANSPLANTATION |
Philadelphia, Pa, and Houston, Tex
From the Divisions of Pediatric Cardiology,a Cardiothoracic Surgery,b and Pathology,c Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, and the Division of Pediatric Cardiology,d Texas Children's Hospital, Baylor College of Medicine, Houston, Tex.
Received for publication Feb 17, 1998. Revisions requested May 26, 1998; revisions received June 26, 1998. Accepted for publication June 29, 1998. Address for reprints: Nancy D. Bridges, MD, Medical Director, Thoracic Organ Transplantation, Children's Hospital of Philadelphia, 34th St and Civic Center Blvd, Philadelphia, PA 19104.
| Abstract |
|---|
|
|
|---|
.002 in each case).| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
Definition of clinical disease and OB
Laboratory evidence of viral infection in the lung was correlated with the presence or absence of clinical disease. A significant lung infection was defined as the presence of at least 2 of the following: new densities on chest radiograph; decreased arterial oxygen saturation, compared with the patient's baseline level; or fever, cough, dyspnea, or new abnormal auscultatory findings. In the context of these clinical findings, the date of diagnosis of viral pneumonitis was defined as the date on which the specimen in which virus was ultimately identified was obtained. OB was diagnosed according to the criteria of the working formulation group of the International Society for Heart and Lung Transplantation
3: that is, the presence of eosinophilic fibrous scarring in the walls of the small conducting airways, with partial or complete obliteration of the lumen. Because only 5 of the 16 patients in this study were mature enough to reliably perform pulmonary function testing, the clinical diagnosis of bronchiolitis obliterans syndrome was not used. However, for each of those 5 patients, the results of pulmonary function testing correlated with the presence or absence of histologically defined OB. Graft survival was defined as the interval between implantation and explantation in the case of patients receiving a second transplant, or from implantation to death in patients who died.
Statistical methods
Variables examined for a statistically significant association with graft survival, patient survival, and OB included adenovirus infection in the lung, other viral infection in the lung (CMV, RSV, influenza B virus, or rhinovirus), age at transplantation, sex, and number of episodes of acute rejection graded A3 or higher. Univariate analysis was performed with the use of the
2 test for discrete variables and regression for continuous variables. Among the variables examined, only adenovirus infection was significantly associated with graft loss, patient survival, or OB. These outcomes were examined by means of the Cox proportional hazards model, with adenovirus infection entered as a time-dependent variable. Statistical analysis was carried out with the use of Stata software (Stata Corporation, College Station, Tex).
| Results |
|---|
|
|
|---|
|
Next in frequency of identification after adenovirus was RSV, which was found 9 times in 8 patients. One patient was identified as having RSV at the time of transplantation, with no clinical illness evident either before or after transplantation. In 7 instances, RSV was associated with a mild respiratory illness characterized by small decreases in arterial oxygen saturation, mild wheezing on auscultation, little or no change in roentgenographic appearance of the lungs, and in 2 instances, gastroenteritis. In 3 of these cases, patients were hospitalized for intravenous hydration, for supplemental oxygen via nasal cannula, or for both treatments. All of these patients recovered without sequelae. In 1 patient (patient 7), RSV was identified in a tracheal aspirate specimen obtained at the time of overwhelming, fatal Pseudomonas sepsis; the significance of this finding is unclear.
Both cases of CMV were associated with significant respiratory disease. In 1 case, CMV was identified concurrently with adenovirus, at a time when the patient was receiving ganciclovir; that patient had fulminant respiratory failure and underwent a second lung transplantation. In the other, the patient's pneumonitis was treated with intravenous ganciclovir, and she recovered. However, OB subsequently developed and she underwent a second lung transplantation.
Both cases of parainfluenza were also associated with significant respiratory disease, characterized by decreased arterial oxygen saturations, increased work of breathing, wheezing on auscultation, and diffuse interstitial densities on chest radiograph. In 1 of these 2 patients, RSV was identified concurrently with parainfluenza. Both patients were hospitalized and treated with intravenous hydration and supplemental oxygen by nasal cannula; both recovered. OB later developed in 1 patient after an episode of adenovirus pneumonia.
Both cases of rhinovirus were associated with mild upper respiratory tract illnesses. Identification of Epstein-Barr virus, herpes simplex virus, and influenza B was not associated with clinical respiratory illness.
Identification of adenovirus in the transplanted lung
In 10 grafts, there was no evidence of adenovirus infection. Of these, 2 are in patients who had adenovirus identified in a prior graft. Thus 8 of 16 patients have been free of adenovirus in the transplanted lung. Among these 8 patients, 6 have no evidence of OB, 1 is free of symptoms but has a histologic diagnosis of OB, and 1 has undergone a second transplant operation because of OB in the first graft.
Adenovirus was identified in 9 grafts over a period of almost 18 months (Table II). In 2 instances, 2 patients were infected within a 1-week period. In the first instance, 1 patient acquired the infection from the donor, and the other acquired it in the community. In the second instance, 2 infections were identified within a 5-day period in patients in the intensive care unit. The other 5 infections were separated by time intervals of 1 to 6 months. The remaining 8 patients (9 grafts) all had evidence of adenovirus infection. One of the grafts was infected with adenovirus on 2 separate occasions, 11 months apart, for a total of 10 infectious episodes in 9 grafts in 8 patients. In patients identified as having adenovirus pneumonia, routine triple-drug immunosuppression was maintained, with tacrolimus or cyclosporine (INN: ciclosporin) levels maintained at the low end of the therapeutic range (6-10 ng/mL or 150- 200 ng/µL, respectively).
|
In 2 patients (3 grafts), adenovirus was identified in the lung by PCR at the time of a clinical pneumonitis, without other laboratory confirmation. No other organisms were identified to account for the clinical findings. In 1 of these patients, fulminant graft failure developed, and the patient underwent a successful second transplant operation; she died 11 months later of respiratory failure, with adenovirus identified only by PCR in the second graft. The other patient had progressive graft failure starting at the time of the adenovirus infection; she died of respiratory failure.
Finally, in 5 patients (5 grafts), adenovirus was identified at the time of clinical pneumonitis by PCR as well as at least 1 other laboratory method. In 2 of these 5, both of whom had early, rapidly progressive infections leading to graft failure, adenovirus was also identified by PCR in the donor lung before implantation. One of these patients had successful retransplantation after a period of support with extracorporeal membrane oxygenation, and the other died while waiting for a second donor organ. Chronic graft failure with histologic evidence of OB and graft vasculopathy developed in a third patient, who had a second transplant operation. Acute severe respiratory failure developed in the fourth patient in this group; although he recovered and is clinically well, he has a histologic diagnosis of OB 1 year later. The last patient in this group had a less severe clinical illness at the time that adenovirus was identified in her lung; she recovered from that episode but died 12 months later of respiratory failure after a second adenovirus lung infection.
Impact of adenovirus on graft and patient survival
Among the 8 patients in whom adenovirus was identified in the transplanted lung, only 2 were still alive at the end of the follow-up period. Both have histologic evidence of OB. Death from respiratory failure occurred in 4 patients 3 weeks, 10 months, 12 months, and 15 months after transplantation, respectively. The other 2 patients died of unrelated extrapulmonary infections after a second lung transplantation (Aspergillus cerebritis in 1, Pseudomonas sepsis in the other), with good graft function.
Among the 19 grafts implanted during the study period, 3 failed abruptly in the immediate postoperative period. Adenovirus was identified in all. Two of these patients underwent a second lung transplantation; the third died before organs became available. In all, 3 patients underwent a second lung transplantation for respiratory failure after adenovirus infection (2 early and 1 late). In only 1 of these 3 patients was adenovirus identified in the second graft, and that patient died of chronic progressive respiratory failure. The other 2 died of unrelated infections, with good graft function.
In a Cox proportional hazards analysis in which adenovirus infection was entered as a time-dependent variable, adenovirus infection was significantly associated with graft loss (P = .002, coefficient 2.67, 95% CI 1.0-4.3), patient death (P < .001, coefficient 37.7, 95% CI 36.9-38.5) and with the histologic diagnosis of OB (P < .0001, coefficient 36.2-37.5, 95% CI 36.2-37.5). Survival with and without adenovirus is depicted in Fig 1; survival without adenovirus infection is taken as the interval from transplantation to last follow-up or to the date of identification of adenovirus infection, at which point patients are censored; survival after adenovirus infection is taken as the interval between identification of adenovirus infection and last follow-up or death. The difference in survival is significant (P = .001 by the Wilcoxon-Gehan test). None of the other variables examined (age, sex, number of episodes of acute rejection, and identification of other viruses in the transplanted lung) were significantly associated with graft loss, death, or OB in this group.
|
| Discussion |
|---|
|
|
|---|
Although the cause of OB remains elusive, there is some consensus that it is a multifactorial, immunologically mediated process.
12,13 Several investigators have demonstrated a relationship between OB and acute cellular rejection, and this relationship appears to be potentiated by infection, most notably CMV.1418 Although neither rejection nor CMV emerged as an important predictor of early or late graft failure in the current analysis, both patients who had CMV pneumonitis eventually had OB and graft failure leading to a second lung transplantation. Thus the lack of statistical significance for these variables is likely due to the small number of patients in this study. It is also possible that these factors are overshadowed by other features (specifically, susceptibility to viral pneumonitis) related to our patients' young age; previous authors have noted that infection with respiratory viruses is a more serious problem in younger transplant recipients.
19
Adenovirus, whether wild type or replication deficient, elicits a strong immune response in the lung.
20 Thus the relationship demonstrated in this study between adenovirus and OB in lung transplant recipients is plausible. Adenovirus pneumonia is a known (though rare) cause of OB in immunocompetent children
21 and has been demonstrated to cause OB in immunocompetent animal models.
22 Adenovirus can be associated with chronic or persistent infection and, in either case, is known to be associated with chronic airway obstruction and deterioration of lung function.
23,24 Finally, adenovirus is a mediator of apoptosis,
25,26 a process that may have a role in the pathogenesis of OB.
27
The prevalence of adenovirus in young patients and the ease with which it is transmitted, particularly as a nosocomial infection,
28,29 make this a troubling finding. Two of the patients in this series who had early graft loss as a result of adenovirus pneumonia received the virus from their donors. Mild viral symptoms in an infant or toddler are so common that this history might be overlooked in the evaluation of a donor. Furthermore, viral respiratory infections of all sorts are common in healthy children, as well as in those who receive transplants. In the early stages of infection, those that are generally benign in transplant recipients, such as RSV and rhinovirus, are clinically indistinguishable from those with more serious consequences, such as adenovirus and parainfluenza. PCR methodology has been demonstrated to be a reliable and clinically useful tool in the specific diagnosis of viral infections in heart transplant recipients.
30 However, given the time constraints that exist at the time of cadaveric donor lung transplantation, reliable confirmation of the presence or absence of adenovirus in a potential donor before transplantation is usually not feasible.
| Summary and conclusions |
|---|
|
|
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
W. G. Nichols, A. J. Peck Campbell, and M. Boeckh Respiratory Viruses Other than Influenza Virus: Impact and Therapeutic Advances Clin. Microbiol. Rev., April 1, 2008; 21(2): 274 - 290. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Mikols, L. Yan, J. Y. Norris, T. D. Russell, A. P. Khalifah, R. R. Hachem, M. M. Chakinala, R. D. Yusen, M. Castro, E. Kuo, et al. IL-12 p80 Is an Innate Epithelial Cell Effector That Mediates Chronic Allograft Dysfunction Am. J. Respir. Crit. Care Med., August 15, 2006; 174(4): 461 - 470. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Milstone, L. M. Brumble, J. Barnes, W. Estes, J. E. Loyd, R. N. Pierson III, and S. Dummer A single-season prospective study of respiratory viral infections in lung transplant recipients Eur. Respir. J., July 1, 2006; 28(1): 131 - 137. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chong, K. S. Lee, T. S. Kim, M. J. Chung, M. P. Chung, and J. Han Adenovirus Pneumonia in Adults: Radiographic and High-Resolution CT Findings in Five Patients. Am. J. Roentgenol., May 1, 2006; 186(5): 1288 - 1293. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.B. Mallory and T.L. Spray Paediatric lung transplantation Eur. Respir. J., November 1, 2004; 24(5): 839 - 845. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Khalifah, R. R. Hachem, M. M. Chakinala, K. B. Schechtman, G. A. Patterson, D. P. Schuster, T. Mohanakumar, E. P. Trulock, and M. J. Walter Respiratory Viral Infections Are a Distinct Risk for Bronchiolitis Obliterans Syndrome and Death Am. J. Respir. Crit. Care Med., July 15, 2004; 170(2): 181 - 187. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Lau, G. A. Patterson, and S. M. Palmer Critical Care Aspects of Lung Transplantation J Intensive Care Med, March 1, 2004; 19(2): 83 - 104. [Abstract] [PDF] |
||||
![]() |
M. Narita, M. Yamada, T. Tsuboi, and K. Kawashima Bovine Adenovirus Type 3 Pneumonia in Dexamethasone-treated Calves Vet. Pathol., March 1, 2003; 40(2): 128 - 135. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Kirshbom, N. D. Bridges, R. J. Myung, J. W. Gaynor, B. J. Clark, and T. L. Spray Use of extracorporeal membrane oxygenation in pediatric thoracic organ transplantation J. Thorac. Cardiovasc. Surg., January 1, 2002; 123(1): 130 - 136. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Shirali, J. Ni, R. E. Chinnock, J. K. Johnston, G. L. Rosenthal, N. E. Bowles, and J. A. Towbin Association of Viral Genome with Graft Loss in Children after Cardiac Transplantation N. Engl. J. Med., May 17, 2001; 344(20): 1498 - 1503. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |